News Archive

Aug 2017

Aug 24, 2017 Starpharma to present at Finance News Network Investor Event

Aug 24, 2017 Starpharma CEO on Finance News Network

Aug 11, 2017 Seeking Alpha covers Starpharma

Aug 10, 2017 Starpharma and Monash awarded STEM+ Business fellowships

Aug 09, 2017 Hope is on the way for one of the world’s most common sexual problems

Aug 09, 2017 Starpharma readies US NDA for VivaGel® on positive results in Phase 3 Bacterial vaginosis

Aug 09, 2017 Starpharma and Monash awarded STEM+ Business Fellowships

Aug 07, 2017 Successful VivaGel® Phase 3 results and NDA planned for rBV

Aug 06, 2017 Biotech clinical trials a star performer

Jul 2017

Jul 19, 2017 Appendix 4C - Quarterly Cashflow Report

Jul 04, 2017 Shareholder Update July 2017

Jul 04, 2017 VivaGel® BV phase 3 results timing and commercialisation

Jun 2017

Jun 23, 2017 Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base

Jun 20, 2017 Starpharma featured on Business IQ, Sky Business News

Jun 14, 2017 Finance News Network: Starpharma sells Agrochemicals business for $35M

Jun 14, 2017 Starpharma’s sale of its agrochemical business to Agrium for A$35M noted in The Land

Jun 14, 2017 Sale of Agrochemicals Business Investor Presentation

Jun 14, 2017 Starpharma sells Agrochemicals business to Agrium for $35M

Jun 06, 2017 DEP® irinotecan outperforms irinotecan in multiple cancer models

Jun 02, 2017 Starpharma receives DEP® milestone from AstraZeneca

Apr 2017

Apr 28, 2017 Appendix 4C - Quarterly Cashflow Report

Apr 20, 2017 Starpharma featured on Ticky on Sky Business News

Apr 20, 2017 AstraZeneca DEP® candidate advance triggers milestone to Starpharma

Apr 12, 2017 Melbourne-based company develops world's first anti-viral condom

Apr 12, 2017 Ansell launches VivaGel® condom in Canada

Mar 2017

Mar 30, 2017 VivaGel BV phase 3 trials for prevention of BV completed

Mar 30, 2017 VivaGel® BV phase 3 trials for prevention of BV completed

Feb 2017

Feb 27, 2017 Interim Report and Half-Yearly Financial Results

Jan 2017

Jan 31, 2017 Appendix 4C - Quarterly Cashflow Report

Jan 19, 2017 Shareholder Update January 2017

Jan 13, 2017 Starpharma VivaGel® BV gets FDA fast track

Jan 12, 2017 VivaGel® BV granted QIDP and Fast Track designation by US FDA

Dec 2016

Dec 22, 2016 Starpharma receives $3.5M R&D tax incentive refund

Nov 2016

Nov 29, 2016 AGM Chairman’s address and CEO presentation

Nov 28, 2016 Starpharma signs license for VivaGel® Condom in Iran

Nov 08, 2016 Starpharma to present at Bio-Europe conference

Oct 2016

Oct 28, 2016 Appendix 4C - Quarterly Cashflow Report

Oct 28, 2016 Additional Priostar® Glyphosate Patent Allowed in US

Oct 26, 2016 Starpharma to present at US Drug Delivery Conference

Oct 25, 2016 Starpharma to present at ASX Spotlight in Asia

Oct 13, 2016 Enrolment complete for Phase 3 VivaGel® BV-R program

Sep 2016

Sep 13, 2016 VivaGel® condom receives regulatory approval in Canada

Aug 2016

Aug 30, 2016 Highlights of FY2016 Presentation: FNN Interview

Aug 29, 2016 Annual Report and full year financial results

Aug 01, 2016 The Australian: Starpharma perks up on China condom deal

Jul 2016

Jul 28, 2016 Starpharma initiates new DEP™ drug delivery program with AstraZeneca

Jul 21, 2016 Starpharma signs license for a VivaGel® condom in China

Jul 14, 2016 Appendix 4C - Quarterly Cashflow Report

May 2016

May 25, 2016 Starpharma’s DEP™ eliminates cabazitaxel neutropenia

May 17, 2016 The Conversation: Antiviral condoms will help protect Australian Olympians from STIs – here’s how